NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/13/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8,504.51 mln
Float394 mln
Earnings Date08/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
4.18
Highly suspicious
1-Year Forecast
15.50
Transformational upside
Relative Strength
90
/ 100
Top performer
Debt / Equity
-1.03
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
ImmunityBio is a San Diego-based biotech company working to fight cancer and infectious diseases by developing treatments that strengthen the body's own immune system. Its most notable product, Anktiva, has received FDA approval for use in certain bladder cancer patients who have not responded to standard therapy. The company works across several treatment approaches, including proteins, vaccines, and cell-based therapies, and collaborates with leading research organizations such as the National Cancer Institute and partners in India and China.
